GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (BSP:LILY34) » Definitions » Net Margin %
中文

Eli Lilly and Co (BSP:LILY34) Net Margin %

: 23.41% (As of Dec. 2023)
View and export this data going back to 2013. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Eli Lilly and Co's Net Income for the three months ended in Dec. 2023 was R$10,729 Mil. Eli Lilly and Co's Revenue for the three months ended in Dec. 2023 was R$45,830 Mil. Therefore, Eli Lilly and Co's net margin for the quarter that ended in Dec. 2023 was 23.41%.

The historical rank and industry rank for Eli Lilly and Co's Net Margin % or its related term are showing as below:

BSP:LILY34' s Net Margin % Range Over the Past 10 Years
Min: -1.02   Med: 15.2   Max: 37.27
Current: 15.36


BSP:LILY34's Net Margin % is ranked better than
81.67% of 1020 companies
in the Drug Manufacturers industry
Industry Median: 3.765 vs BSP:LILY34: 15.36

Eli Lilly and Co Net Margin % Historical Data

The historical data trend for Eli Lilly and Co's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.27 25.24 19.71 21.88 15.36

Eli Lilly and Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.54 19.32 21.21 -0.60 23.41

Competitive Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Net Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Net Margin % distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Net Margin % falls into.



Eli Lilly and Co Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Eli Lilly and Co's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=25676.912/167201.265
=15.36 %

Eli Lilly and Co's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=10729.092/45829.789
=23.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eli Lilly and Co  (BSP:LILY34) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Eli Lilly and Co Net Margin % Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (BSP:LILY34) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Co (BSP:LILY34) Headlines

No Headlines